Calmark strengthens the team with a software developer
Calmark Sweden AB has recruited Balázs Szabó in the role of junior software developer. The employment begins on August 17.
Balázs Szabó is finishing his Master’s degree in Medical Engineering at KTH and has a background as a Mechatronics Engineer. Moreover, he has experience in firmware development from the MedTech company Norma Diagnostika, a Hungarian company that specialized in the designing and manufacturing of high quality and innovative blood analysis systems serving the in-vitro diagnostic (IVD) market.
"I look forward to beginning my work at Calmark in this exciting phase", says Balázs Szabó. "I am glad to be contributing with my knowledge and experience in the continued product development."
“We are very pleased to welcome Balázs to the team”, says Anna Söderlund, CEO of Calmark. “His background is perfect for Calmark. In the past we have had software development via external resources and I am happy that we can now strengthen the team with this important competence internally."
Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
For more information about Calmark Sweden AB, please contact:
Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se
www.calmark.se
Calmark Sweden AB is a medical technology company developing a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a reader and single-use products. The first three tests are being launched in 2020. WHO expects 1.5 billion children to be born worldwide prior to 2030. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer decision-making support, which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.
Tags:
